New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
18:05 EDTMNOVMedicNova announces publication of positive phase 2 clinical results
MediciNova announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication reports on two Phase 2a clinical trials conducted by MediciNova, MN-221-CL-004 and MN-221-CL-005, which assessed the safety, tolerability, and FEV1 improvements in mild-moderate and moderate-to-severe asthmatics, respectively. MN-221 is designed to treat acute exacerbations via intravenous infusion, bypassing constricted airways to deliver the drug directly to the lungs. Preclinical studies showed MN-221 to have a high affinity for the beta(2)-adrenergic receptor, found primarily in the lungs, and a much lower affinity for the beta(1)-adrenergic receptor found primarily in cardiac tissue. These studies showed no worrisome increase in heart rate when MN-221 was administered.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
09:19 EDTMNOVOn The Fly: Pre-market Movers
Subscribe for More Information
August 18, 2015
19:48 EDTMNOVMediciNova 5M share Spot Secondary priced at $3.50
Subscribe for More Information
18:32 EDTMNOVOn The Fly: After Hours Movers
Subscribe for More Information
16:01 EDTMNOVMediciNova files to sell common stock, no amount given
MediciNova intends to use the net proceeds received from this offering to fund continued research and development efforts, including with respect to its MN-166 and MN-001 product candidates, and for general corporate purposes, including working capital. Ladenburg Thalmann is acting as sole book-running manager of the offering, and Mizuho Securities and SMBC Nikko are acting as co-managers of the offering.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use